13F 申报指南13F 概念全攻略
什么是 SEC Form 13F 申报？美股机构大户持股全攻略
完整解读 Form 13F 申报规范、1 亿美元门槛与 45 天延迟申报机制，学会如何追踪顶级对冲基金与机构法人持仓动向。
AlphaSMO 权威研究指南阅读专题
CIK: 0001617201
申报总市值
US$5.8亿
US$5.8亿
36 檔
22.6%
Prosight Management, LP 在 Q4 2024 季度的美股仓位总计估值为 US$5.8亿，分散于 36 个持仓标的之中，反映其市场参与广度与投资规模。
在 Q4 2024，Prosight Management, LP 展现出较为审慎的避险与获利了结姿态。本季共减仓 15 个仓位并完全清仓 17 档持股，调降曝光的仓位数量高于加仓动作。
在资产配置集中度方面，Prosight Management, LP 的前 5 大核心持股（包含 LKFT, ACHC, BBIO 等）合计占整体申报市值的 22.6%，反映机构在主要关键仓位上的权重分布。
| # | 代码 | 标的名称 | 资产子类别 | 占比 | 占比变动 | 持仓量变化 | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | LKFT | Lakefront Biotherapeutic-adr | 股票-其他 | 7.79% | +2.93% | -0.37% | |
| 2 | ACHC | Acadia Healthcare Co Inc | 股票-其他 | 7.58% | — | +12113.20% | |
| 3 | BBIO | Bridgebio Pharma Inc | 股票-医疗保健 | 7.55% | — | -8.45% | |
| 4 | MGTX | MeiraGTx Holdings plc | 股票-其他 | 7.39% | -3.52% | -10.40% | |
| 5 | ABCL | Abcellera Biologics Inc | 股票-其他 | 5.95% | — | -19.05% | |
| 6 | ✓ | Adc Therapeutics SA | 股票-其他 | 5.23% | -3.66% | -1.26% | |
| 7 | MIRM | Mirum Pharmaceuticals Inc | 股票-其他 | 5.16% | — | -3.16% | |
| 8 | ICLR | ICON Public Limited Company | 股票-医疗保健 | 4.93% | — | — | |
| 9 | ROIV | Roivant Sciences Ltd. | 股票-医疗保健 | 4.90% | -0.82% | EXIT | |
| 10 | JANX | Janux Therapeutics Inc | 股票-其他 | 4.88% | +1.98% | +60.86% | |
| 11 | SDGR | Schrodinger Inc | 股票-其他 | 3.84% | -0.95% | EXIT | |
| 12 | RCKT | Rocket Pharmaceuticals Inc | 股票-其他 | 3.78% | +0.01% | +583.14% | |
| 13 | ZYME | Zymeworks Inc | 股票-其他 | 3.32% | +0.83% | -10.64% | |
| 14 | KURA | Kura Oncology Inc | 股票-其他 | 3.19% | -0.66% | +87.91% | |
| 15 | AM6 | Amicus Therapeutics Inc | 股票-其他 | 2.40% | — | — | |
| 16 | ZBH | Zimmer Biomet Holdings Inc | 股票-医疗保健 | 2.34% | — | -51.69% | |
| 17 | SNDX | Syndax Pharmaceuticals Inc | 股票-其他 | 2.27% | +1.57% | +11.89% | |
| 18 | STTK | Shattuck Labs Inc | 股票-其他 | 2.22% | +1.84% | +16.91% | |
| 19 | IMVT | Immunovant Inc | 股票-其他 | 2.09% | -0.72% | EXIT | |
| 20 | 2655787D | Blueprint Medicines CORP | 股票-其他 | 1.62% | — | +42.25% | |
| 21 | PRTA | Prothena Corporation plc | 股票-其他 | 1.60% | — | -13.52% | |
| 22 | ✓ | Galapagos NV | 股票-其他 | 1.34% | — | — | |
| 23 | CTMX | Cytomx Therapeutics Inc | 股票-其他 | 1.11% | — | +29.21% | |
| 24 | HAE | Haemonetics Corp/mass | 股票-其他 | 1.01% | — | -28.15% | |
| 25 | CNC | Centene CORP | 股票-医疗保健 | 0.92% | — | — | |
| 26 | SGHT | Sight Sciences Inc | 股票-其他 | 0.91% | — | +71.09% | |
| 27 | LIVN | LivaNova PLC | 股票-其他 | 0.90% | — | -22.22% | |
| 28 | CRBP | Corbus Pharmaceuticals Holdi | 股票-其他 | 0.88% | -0.02% | +107.69% | |
| 29 | ERAS | Erasca Inc | 股票-其他 | 0.66% | — | -52.26% | |
| 30 | SYRE | Spyre Therapeutics Inc | 股票-其他 | 0.51% | — | — | |
| 31 | CDNA | Caredx Inc | 股票-其他 | 0.47% | — | — | |
| 32 | ✓ | Mural Oncology Pub LTD Co | 股票-其他 | 0.42% | — | -18.19% | |
| 33 | FTRE | Fortrea Holdings Inc | 股票-医疗保健 | 0.28% | — | — | |
| 34 | RNTX | Rein Therapeutics Inc | 股票-其他 | 0.26% | +0.11% | +8.82% | |
| 35 | IMNM | Immunome Inc | 股票-其他 | 0.16% | — | +38.86% | |
| 36 | OKUR | Onkure Therapeutics Inc-a | 股票-其他 | 0.15% | -0.69% | — |
| # | 代码 | 标的名称 | 占比变动 | 持仓量变化 | 异动类型 |
|---|---|---|---|---|---|
| 1 | ACHC | Acadia Healthcare Co Inc | +7.5% | +12113.20% | 加仓 |
| 2 | ICLR | ICON Public Limited Company | +4.9% | NEW | 新建仓 |
| 3 | RCKT | Rocket Pharmaceuticals Inc | +3.1% | +583.14% | 加仓 |
| 4 | JANX | Janux Therapeutics Inc | +2.6% | +60.86% | 加仓 |
| 5 | AM6 | Amicus Therapeutics Inc | +2.4% | NEW | 新建仓 |
| 6 | MGTX | MeiraGTx Holdings plc | +2.4% | -10.40% | 减仓 |
| 7 | ✓ | Galapagos NV | +1.3% | NEW | 新建仓 |
| 8 | CNC | Centene CORP | +0.9% | NEW | 新建仓 |
| 9 | BBIO | Bridgebio Pharma Inc | +0.7% | -8.45% | 减仓 |
| 10 | MIRM | Mirum Pharmaceuticals Inc | +0.7% | -3.16% | 减仓 |
| 11 | SDGR | Schrodinger Inc | +0.6% | +2.93% | 加仓 |
| 12 | 2655787D | Blueprint Medicines CORP | +0.6% | +42.25% | 加仓 |
| 13 | SYRE | Spyre Therapeutics Inc | +0.5% | NEW | 新建仓 |
| 14 | LKFT | Lakefront Biotherapeutic-adr | +0.5% | -0.37% | 减仓 |
| 15 | ZYME | Zymeworks Inc | +0.5% | -10.64% | 减仓 |
| 16 | CDNA | Caredx Inc | +0.5% | NEW | 新建仓 |
| 17 | FTRE | Fortrea Holdings Inc | +0.3% | NEW | 新建仓 |
| 18 | CTMX | Cytomx Therapeutics Inc | +0.2% | +29.21% | 加仓 |
| 19 | CRBP | Corbus Pharmaceuticals Holdi | +0.2% | +107.69% | 加仓 |
| 20 | OKUR | Onkure Therapeutics Inc-a | +0.2% | NEW | 新建仓 |
| 21 | ABCL | Abcellera Biologics Inc | +0.1% | -19.05% | 减仓 |
| 22 | SGHT | Sight Sciences Inc | +0.1% | +71.09% | 加仓 |
| 23 | IMNM | Immunome Inc | 0% | +38.86% | 加仓 |
| 24 | ROIV | Roivant Sciences Ltd. | 0% | -12.87% | 减仓 |
| 25 | ✓ | Mural Oncology Pub LTD Co | 0% | -18.19% | 减仓 |
| 26 | RNTX | Rein Therapeutics Inc | -0.1% | +8.82% | 加仓 |
| 27 | ✓ | Shattuck Labs Inc | -0.1% | EXIT | 清仓 |
| 28 | IMRX | Immuneering CORP - Class A | -0.1% | EXIT | 清仓 |
| 29 | KURA | Kura Oncology Inc | -0.2% | +87.91% | 加仓 |
| 30 | OVID | Ovid Therapeutics Inc | -0.2% | EXIT | 清仓 |
| 31 | SEM | Select Medical Holdings CORP | -0.2% | EXIT | 清仓 |
| 32 | ✓ | Corvel CORP | -0.2% | EXIT | 清仓 |
| 33 | LIVN | LivaNova PLC | -0.3% | -22.22% | 减仓 |
| 34 | HAE | Haemonetics Corp/mass | -0.3% | -28.15% | 减仓 |
| 35 | SNDX | Syndax Pharmaceuticals Inc | -0.4% | +11.89% | 加仓 |
| 36 | PRTA | Prothena Corporation plc | -0.4% | -13.52% | 减仓 |
| 37 | ✓ | Vincerx Pharma Inc | -0.4% | EXIT | 清仓 |
| 38 | MRVI | Maravai Lifesciences Hldgs-a | -0.4% | EXIT | 清仓 |
| 39 | IMVT | Immunovant Inc | -0.5% | -17.43% | 减仓 |
| 40 | ERAS | Erasca Inc | -0.7% | -52.26% | 减仓 |
| 41 | VKTX | Viking Therapeutics Inc | -0.8% | EXIT | 清仓 |
| 42 | TECX | Tectonic Therapeutic Inc | -1% | EXIT | 清仓 |
| 43 | ✓ | Cassava Sciences Inc | -1.1% | EXIT | 清仓 |
| 44 | COGT | Cogent Biosciences Inc | -1.1% | EXIT | 清仓 |
| 45 | ✓ | Ishares Tr | -1.6% | EXIT | 清仓 |
| 46 | NBIX | Neurocrine Biosciences Inc | -1.8% | EXIT | 清仓 |
| 47 | ZBH | Zimmer Biomet Holdings Inc | -2.1% | -51.69% | 减仓 |
| 48 | ✓ | Adc Therapeutics SA | -2.2% | -1.26% | 减仓 |
| 49 | CYTK | Cytokinetics Inc | -2.5% | EXIT | 清仓 |
| 50 | DXCM | Dexcom Inc | -2.6% | EXIT | 清仓 |
根据 SEC 官方 Form 13F 申报备案，Prosight Management, LP 在 Q4 2024 季度的美股持仓总市值约为 US$5.8亿，共申报了 36 个公开持股仓位。
在 Q4 2024 季度，Prosight Management, LP 按市值排列的前三大核心持股分别为：LKFT (7.8%)、ACHC (7.6%)、BBIO (7.5%)。其中最大持股仓位 LKFT 占据整体投资组合约 7.8% 的权重。
精选 AlphaSMO 大户持股与内部人交易深度分析，提升投资决策胜率
完整解读 Form 13F 申报规范、1 亿美元门槛与 45 天延迟申报机制，学会如何追踪顶级对冲基金与机构法人持仓动向。
本季最大新建仓标的
ICLR
市值: US$1782.5万
本季最大获利了结 / 清仓标的
MCK
前期市值: US$1771.1万
在 Q4 2024 季度中，Prosight Management, LP 共进行了 53 项持仓异动，包含新建仓 8 个仓位、加仓 13 个仓位、减仓 15 个仓位以及清仓 17 个仓位。 其中最大新建仓标的为 ICLR。 本季清仓仓位包含 MCK。
本页面所有持股数据均直接同步自美国证券交易委员会（SEC）EDGAR 官方系统之 13F-HR / 13F-HR/A 季度申报文件。AlphaSMO 通过机器解析 CUSIP 与个股对照，提供 100% 精准对齐的历史时序数据集，并支持 Schema.org 结构化数据格式。
解析公司高管、董事与 10% 大股东之 Form 4 内部人交易申报，掌握高管自家股票买卖第一手信号。
深入剖析 5% 股权申报门槛、13D 与 13G 之差异，以及最新 SEC 申报时程规范，洞察机构法人的激进投资动向。